MedTrace Logo

A Study of Safety & Blood Levels of IDL-2965 in Healthy Subjects and Patients With a Special Type of Pulmonary Fibrosis

NCT03949530 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-08-04

No results posted yet for this study

Summary

The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.

Conditions

Interventions

DRUG

IDL-2965 Oral Capsule

Investigational drug

DRUG

Placebos

Placebo

Sponsors & Collaborators

  • Indalo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jim Bush, MRCS FFPM · Indalo Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-16
Primary Completion
2020-03-29
Completion
2020-03-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03949530 on ClinicalTrials.gov